Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

AstraZeneca1,849 enrolled

Overview

The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy

Study Type

OBSERVATIONAL

Enrollment

1,849

Conditions

Type 2 Diabetes

Eligibility

Sex: ALLMin age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients have an established diagnosis of T2D * Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program Exclusion Criteria: * Experience of therapy with two or more OADs and/or insulin therapy and/or incretin mimetics (exenatide) at any time before registration in the Program * Absence of changes in HbAc1 level during the last year before registration in the Program

Locations (23)

Research Site

Arkhangelsk, Russia

Research Site

Astrakhan, Russia